LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature. It also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, the company offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes that cuts valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, it provides vascular patches, which are used for closure of vessels after surgical intervention, as well as endarterectomy and other vascular reconstruction; vessel closure systems to attach vessels to one another with titanium clips instead of sutures; and Reddick cholangiogram catheters to inject dye into the cystic duct during laparoscopic cholecystectomy, as well as laparoscopic accessory for use in laparoscopic gall bladder removal. LeMaitre Vascular, Inc. markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was founded in 1983 and is headquartered in Burlington, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:LMAT
CUSIPN/A
Phone781-221-2266
Debt
Debt-to-Equity RatioN/A
Current Ratio7.05
Quick Ratio5.39
Price-To-Earnings
Trailing P/E Ratio42.86
Forward P/E Ratio34.45
P/E Growth2.28
Sales & Book Value
Annual Sales$100.87 million
Price / Sales7.06
Cash Flow$1.1102 per share
Price / Cash33.20
Book Value$5.70 per share
Price / Book6.47
Profitability
EPS (Most Recent Fiscal Year)$0.86
Net Income$17.17 million
Net Margins21.09%
Return on Equity19.49%
Return on Assets17.06%
Miscellaneous
Employees423
Outstanding Shares19,310,000
Market Cap$706.45 million
LeMaitre Vascular (NASDAQ:LMAT) Frequently Asked Questions
What is LeMaitre Vascular's stock symbol?
LeMaitre Vascular trades on the NASDAQ under the ticker symbol "LMAT."
How often does LeMaitre Vascular pay dividends? What is the dividend yield for LeMaitre Vascular?
LeMaitre Vascular announced a quarterly dividend on Friday, July 27th. Investors of record on Wednesday, August 22nd will be paid a dividend of $0.07 per share on Thursday, September 6th. This represents a $0.28 annualized dividend and a yield of 0.76%. The ex-dividend date of this dividend is Tuesday, August 21st. View LeMaitre Vascular's Dividend History.
How will LeMaitre Vascular's stock buyback program work?
LeMaitre Vascular announced that its board has approved a stock repurchase plan on Friday, July 28th 2017, which authorizes the company to repurchase $7,500,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 1.4% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company's board believes its stock is undervalued.
How were LeMaitre Vascular's earnings last quarter?
LeMaitre Vascular Inc (NASDAQ:LMAT) issued its quarterly earnings results on Thursday, July, 26th. The medical instruments supplier reported $0.21 EPS for the quarter, missing analysts' consensus estimates of $0.42 by $0.21. The medical instruments supplier earned $27.02 million during the quarter, compared to analyst estimates of $27.09 million. LeMaitre Vascular had a return on equity of 19.49% and a net margin of 21.09%. The company's revenue for the quarter was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.23 EPS. View LeMaitre Vascular's Earnings History.
When is LeMaitre Vascular's next earnings date?
What guidance has LeMaitre Vascular issued on next quarter's earnings?
LeMaitre Vascular issued an update on its FY18 earnings guidance on Thursday, July, 26th. The company provided EPS guidance of $1.04-1.11 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.98. The company issued revenue guidance of $105.3-107.9 million, compared to the consensus revenue estimate of $108.06 million.LeMaitre Vascular also updated its Q3 guidance to $0.20-0.22 EPS.
What price target have analysts set for LMAT?
6 equities research analysts have issued 12 month price targets for LeMaitre Vascular's stock. Their forecasts range from $34.00 to $45.00. On average, they expect LeMaitre Vascular's share price to reach $37.6667 in the next year. This suggests a possible upside of 2.2% from the stock's current price. View Analyst Price Targets for LeMaitre Vascular.
What is the consensus analysts' recommendation for LeMaitre Vascular?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for LeMaitre Vascular.
Who are some of LeMaitre Vascular's key competitors?
Some companies that are related to LeMaitre Vascular include Irhythm Technologies (IRTC), Nevro (NVRO), Tandem Diabetes Care (TNDM), Glaukos (GKOS), Mazor Robotics (MZOR), Cardiovascular Systems (CSII), Luminex (LMNX), Cryolife (CRY), Atrion (ATRI), AtriCure (ATRC), Tactile Systems Technology (TCMD), OraSure Technologies (OSUR), Orthofix International (OFIX), Cerus (CERS) and SurModics (SRDX).
Who are LeMaitre Vascular's key executives?
LeMaitre Vascular's management team includes the folowing people:
- Mr. George W. LeMaitre, Chairman & CEO (Age 53)
- Mr. David B. Roberts, Pres & Director (Age 54)
- Mr. Joseph P. Pellegrino Jr., CFO, Treasurer, Sec. & Director (Age 53)
- Mr. Trent G. Kamke, Sr. VP of Operations (Age 47)
- Dr. George D. LeMaitre, Founder and Chairman of Scientific Advisory Board (Age 84)
Has LeMaitre Vascular been receiving favorable news coverage?
Media headlines about LMAT stock have trended somewhat positive on Friday, according to Accern. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. LeMaitre Vascular earned a media and rumor sentiment score of 0.00 on Accern's scale. They also assigned headlines about the medical instruments supplier an impact score of 46.59 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for LeMaitre Vascular.
Who are LeMaitre Vascular's major shareholders?
LeMaitre Vascular's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.56%), Conestoga Capital Advisors LLC (7.21%), Dimensional Fund Advisors LP (5.21%), Epoch Investment Partners Inc. (4.83%), Janus Henderson Group PLC (3.58%) and Bank of New York Mellon Corp (1.28%). Company insiders that own LeMaitre Vascular stock include Cornelia W Lemaitre, David B Roberts, George W Lemaitre, Lawrence J Jasinski, Michael T Wijas, Peter R Gebauer and Trent G Kamke. View Institutional Ownership Trends for LeMaitre Vascular.
Which major investors are selling LeMaitre Vascular stock?
LMAT stock was sold by a variety of institutional investors in the last quarter, including Algert Global LLC, Renaissance Technologies LLC, Bank of America Corp DE, American Century Companies Inc., Federated Investors Inc. PA, Fiera Capital Corp, King Luther Capital Management Corp and Municipal Employees Retirement System of Michigan. Company insiders that have sold LeMaitre Vascular company stock in the last year include David B Roberts, George W Lemaitre, Lawrence J Jasinski and Trent G Kamke. View Insider Buying and Selling for LeMaitre Vascular.
Which major investors are buying LeMaitre Vascular stock?
LMAT stock was purchased by a variety of institutional investors in the last quarter, including Epoch Investment Partners Inc., Citadel Advisors LLC, Conestoga Capital Advisors LLC, BlackRock Inc., Janus Henderson Group PLC, Royce & Associates LP, Russell Investments Group Ltd. and Convergence Investment Partners LLC. View Insider Buying and Selling for LeMaitre Vascular.
How do I buy shares of LeMaitre Vascular?
Shares of LMAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is LeMaitre Vascular's stock price today?
One share of LMAT stock can currently be purchased for approximately $36.86.
How big of a company is LeMaitre Vascular?
LeMaitre Vascular has a market capitalization of $706.45 million and generates $100.87 million in revenue each year. The medical instruments supplier earns $17.17 million in net income (profit) each year or $0.86 on an earnings per share basis. LeMaitre Vascular employs 423 workers across the globe.
How can I contact LeMaitre Vascular?
LeMaitre Vascular's mailing address is 63 SECOND AVENUE, BURLINGTON MA, 01803. The medical instruments supplier can be reached via phone at 781-221-2266.
MarketBeat Community Rating for LeMaitre Vascular (NASDAQ LMAT)
MarketBeat's community ratings are surveys of what our community members think about LeMaitre Vascular and other stocks. Vote "Outperform" if you believe LMAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LMAT will underperform the S&P 500 over the long term. You may vote once every thirty days.
